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Abstract
Genetic reprogramming of human somatic cells to induced pluripotent stem cells (iPSCs) could offer replenishable cell
sources for transplantation therapies. To fulfill their promises, human iPSCs will ideally be free of exogenous DNA (footprint-
free), and be derived and cultured in chemically defined media free of feeder cells. Currently, methods are available to
enable efficient derivation of footprint-free human iPSCs. However, each of these methods has its limitations. We have
previously derived footprint-free human iPSCs by employing episomal vectors for transgene delivery, but the process was
inefficient and required feeder cells. Here, we have greatly improved the episomal reprogramming efficiency using a
cocktail containing MEK inhibitor PD0325901, GSK3b inhibitor CHIR99021, TGF-b/Activin/Nodal receptor inhibitor A-83-01,
ROCK inhibitor HA-100 and human leukemia inhibitory factor. Moreover, we have successfully established a feeder-free
reprogramming condition using chemically defined medium with bFGF and N2B27 supplements and chemically defined
human ESC medium mTeSR1 for the derivation of footprint-free human iPSCs. These improvements enabled the routine
derivation of footprint-free human iPSCs from skin fibroblasts, adipose tissue-derived cells and cord blood cells. This
technology will likely be valuable for the production of clinical-grade human iPSCs.
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Introduction
Human induced pluripotent stem cells (iPSCs), similar to
human embryonic stem cells (ESCs), are capable of unlimited
proliferation and have the potential to differentiate into all cell
types of the body [1–2]. These cells, thus, have applications in
basic biology, disease modeling, drug development, and trans-
plantation therapies. By expressing a defined set of reprogram-
ming factors, iPSCs have been generated from many cell types of
different species [1–8]. Initial methods for iPSC generation
employed genome-integrating retroviral or lentiviral vectors [2–
3]. These approaches could produce tumorigenic insertional
mutations, and residual or reactivation of transgene expression
during iPSC differentiation could affect lineage choice and the
functionality of iPSC derivatives [2,9]. To overcome these
problems, various methods were developed to derive iPSCs free
of exogenous DNA (footprint-free), including repeated treatments
with reprogramming factors (plasmids, minicircle DNA, non-
integrating adenoviral vectors and proteins), transposons and RNA
viral vectors [10–16]. However, these methods suffer one or more
of the following limitations: the unacceptable low reprogramming
efficiency; the labor-intensive removal of reprogramming factors
from iPSCs; the requirement for viral packaging or feeder cells.
Thus, there is a need to develop a simple and efficient feeder-free
method to enable the routine derivation of footprint-free iPSCs
from many human donor samples, and eventually the derivation of
clinical-grade human iPSCs.
A recent report described the efficient derivation of footprint-
free human iPSCs from fibroblasts using synthetic modified
mRNA [17]. Compared to viral and DNA-based reprogramming
methods, the mRNA-mediated transgene delivery offers a safer
approach for the derivation of clinical-grade human iPSCs. The
requirement for repeated transfections, however, limits the
application of this method to cells types that are easily
transfectable such as skin fibroblasts. It remains to be seen
whether this method can be readily adapted to cells that are
relatively resistant to lipid-mediated transfections, such as cells of
hematopoietic lineages. In addition to the mutations arising during
reprogramming, somatic mutations present in the donor cells may
also significantly affect the safety of human iPSCs. Therefore, the
selection of appropriate donor cell types will likely be important for
the derivation of clinical-grade human iPSCs. A reprogramming
method that is applicable to different cell types will be highly
desirable to address this question. Additionally, recent data suggest
the retention of donor cell epigenetic memory in early passage
iPSCs [18], which influences their in vitro differential capacity. It
remains to be seen whether this is affected by the specific methods
employed in the derivation of iPSCs. Thus alternative methods are
needed for the efficient derivation of human footprint-free iPSCs.
We have previously generated footprint-free human iPSCs using
oriP/EBNA-1 (Epstein-Barr nuclear antigen-1) episomal vectors to
deliver reprogramming genes (OCT4, SOX2, NANOG, LIN28, c-
MYC, KLF4 and SV40LT) [19]. Compared to other methods, this
approach has several advantages. First, the oriP/EBNA-1 vectors
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method to many human cell types. Second, it does not require
viral packaging. Third, no repeated treatments with reprogram-
ming factors are needed. A single transfection of episomal vectors
is sufficient for the derivation of human iPSCs. Moreover, higher
transfection efficiency can be achieved with these vectors due to
the oriP/EBNA-1-mediated nuclear import and retention of
vector DNA [20]. Fourth, the oriP/EBNA-1 vectors replicate
once per cell cycle and are generally present at low copy number
per cell, thus minimizing DNA rearrangement and genome
integration [21]. Last, the removal of episomal vectors from
human iPSCs can be accomplished by simple cell culture without
any additional manipulation, due to the silencing of the viral
promoter driving EBNA-1 expression in iPSCs, and the inherent
instability of oriP/EBNA-1 episomal state - stably established
episomes are lost from cells at a rate of ,5% per cell generation
due to defects in vector synthesis and partitioning [22]. However,
despite these advantages, our original episomal method yielded
low reprogramming efficiency (,3 iPSC colonies from ,1610
6
input human foreskin fibroblasts), and used mouse embryonic
fibroblast (MEF) feeder cells, which seriously limit the industrial
and therapeutic applications of this method.
In this report, we have made significant improvement of the
episomal reprogramming method. Using chemically defined
media, we have established a small molecule-aided feeder-free
reprogramming condition for the efficient derivation of footprint-
free human iPSCs from skin fibroblasts, adipose tissue derived cells
and cord blood cells. This method can be readily adapted to the
derivation of clinical-grade human iPSCs. Of particular interest,
iPSC derivation with this method appeared to progress through a
distinct intermediate stage. It will be interesting to find out how
this small-molecule aided episomal reprogramming method
compares to other reprogramming methods in terms of the
quality of iPSCs they generate.
Results
Identifying small molecules for improved episomal
reprogramming
We have previously developed an oriP/EBNA-1-based episomal
reprogramming approach for the derivation of footprint-free
human iPSCs [19]. The reprogramming efficiency with this
method, however, was prohibitively low (,3 iPSC colonies from
,1610
6 input fibroblasts). This low reprogramming efficiency was
likely due to the loss of oriP/EBNA-1 vectors (.25% per cell
generation) and DNA methylation-mediated transgene silencing
during the first two weeks post-transfection, a time window
required for successful iPSC generation [23]. Thus, small
molecules that could either accelerate reprogramming process,
or reduce episomal vector loss and transgene silencing during the
first two weeks post-transfection, were expected to improve
episomal reprogramming. To identify such small molecules, we
tested chemical compounds that were previously implicated in
reprogramming and epigenetic modifications, using a two-vector
episomal combination containing expression cassettes for all seven
transgenes (OCT4, SOX2, NANOG, LIN28, c-MYC, KLF4 and
SV40LT) (7F-1, Fig. S1A), human foreskin fibroblasts as donor
cells and traditional reprogramming conditions (MEF feeder cells
and human ESC medium). We found that the episomal
reprogramming efficiency could be greatly enhanced with the
addition of a MEK inhibitor PD0325901, a GSK3b inhibitor
CHIR99021, and a TGF-b/Activin/Nodal receptor inhibitor A-
83-01 (Fig. 1A). Previous studies showed that TGF-b signaling
inhibitors together with the MEK inhibitor PD0325901 resulted in
.100-fold increase in the viral reprogramming efficiency [24]. As
shown in Figure 1A, the TGF-b signaling inhibitor A-83-01, either
alone or together with the MEK inhibitor PD0325901, had
minimal effect on episomal reprogramming. All three inhibitors
PD0325901, CHIR99021, and A-83-01 were required to achieve
the maximal increase in reprogramming efficiency. Human
leukemia inhibitory factor (hLIF), though did not significantly
improve episomal reprogramming efficiency, increased the
proliferation of reprogramming intermediates and the reprogram-
ming pace. The ROCK inhibitor HA-100, though had minimal
effect on its own, further increased the episomal reprogramming
efficiency in the presence of PD0325901, CHIR99021, A-83-01
and hLIF. The increase in the episomal reprogramming efficiency
correlated with the duration of small molecule treatment (Fig. 1B).
Early treatment, i.e. between day 1 and 5 post-transfection, though
not sufficient on its own, appeared to be important for the
maximal effect of small molecules on episomal reprogramming.
The observation that episomal reprogramming could be
significantly improved by the continuous presence of PD0325901,
CHIR99021, A-83-01 and hLIF raised an interesting question
about the identity of iPSCs generated. Based on the gene expression
and culture requirements, recent studies suggest that human ESCs
are in a pluripotent state similar to mouse epiblast-derived stem cells
(EpiSCs), and different from mouse ESCs derived from earlier
blastocyst stage, which were proposed to be in a naı ¨ve ground state
of pluripotency [25]. In the presence of PD0325901, CHIR99021,
A-83-01 and hLIF, human ESCs and human ESC-like iPSCs
differentiatedrapidly. On the contrary, these molecules were able to
expand mouse ESC-like human iPSCs from reprogramming
cultures that were not previously exposed to these small molecules
[26]. These mouse ESC-like human iPSCs readily differentiated
following withdrawal of the small molecules. Surprisingly, the
humanepisomaliPSCsobtained inthe continuouspresenceofsmall
molecules expanded well under conditions for human ESCs
(without small molecules), but underwent extensive differentiation
when cultured in the same condition used for their derivation, i.e. in
the presence of small molecules (Fig. 1C), suggesting that these
iPSCs wereina pluripotent state similar to human ESCs, not mouse
ESCs. The seemingly conflicting results could be explained by the
presence of activities that mitigated the effectiveness of small
molecules in the MEF feeder cells and human ESC medium used
for reprogramming (e.g. ligands for TGF-b signaling), which might
enable the generation of human ESC-like pluripotent state in the
presence of small molecules.
Developing a feeder-free episomal reprogramming
condition with defined media
Since the MEF feeder cells and human ESC medium used for
reprogramming likely contains small molecule-mitigating activi-
ties, it is possible to further improve episomal reprogramming by
using matrix and defined culture media. Such defined reprogram-
ming conditions will not only reduce the quality variations
associated with feeder cells and KnockOut serum replacement in
the human ESC medium, but also can be readily adapted to the
production of clinical-grade human iPSCs. To find defined media
that could support episomal reprogramming, we initially tested the
N2B27 medium since it has a simple formulation and was able to
support the proliferation of human ESCs when supplemented with
cytokines [27]. As shown in Figure 2A, the N2B27 medium
supplemented with small molecules gave rise to nearly 6-fold
higher number of colonies stained positive for alkaline phosphatase
(a human pluripotent stem cell marker) (test 2 vs. test 1). These
colonies (piPSC for partially reprogrammed iPSCs) had a mouse
ESC-like domed morphology, which differs from the flattened
Small Molecules Improve Episomal Reprogramming
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(Fig. 2B). They could be expanded for more than 10 passages in
the N2B27 medium supplemented with small molecules. Flow
cytometry analysis of these cells, however, showed no expression of
human ESC-specific cell surface antigens (SSEA-3, SSEA-4, Tra-
1-60 and Tra-1-81), while the expression of a fibroblast marker
CD44 was present (Fig. S2A). Quantitative RT-PCR analysis also
failed to detect any expression of the endogenous OCT4 and
NANOG, two essential markers for human pluripotent stem cells
(Fig. 2C). These results suggested that the colonies were partially
reprogrammed iPSCs, not human ESC-like iPSCs as those derived
with the human ESC medium (test 1) or mouse ESC-like iPSCs,
thus illustrating the important influence of reprogramming culture
conditions on the pluripotent state of iPSCs [28–29]. Interestingly,
the piPSCs contained abundant episomal vectors and maintained
high-level transgene expression even after multiple passages in the
N2B27 medium supplemented with small molecules (Fig. 2C and
Fig. S2B), suggesting a likely mechanism that these small molecules
improved episomal reprogramming was through the retention of
episomal vectors and transgene expression. Removal of small
molecules led to occasional emergence of human ESC-like iPSCs
after two weeks’ culture of piPSCs in the chemically defined
human ESC medium mTeSR1. Thus, although the N2B27
medium failed to yield authentic iPSCs, modifications could be
made in the reprogramming protocol to enable the derivation of
human ESC-like iPSCs using the N2B27 medium.
To this end, we divided the reprogramming process into three
stages: transfection of human somatic cells with episomal repro-
gramming vectors (stage 1), reprogramming using N2B27 medium
supplemented with small molecules (stage 2), and expansion with
mTeSR1 medium (stage 3) (Fig. 2A). When the N2B27 medium
supplemented with small molecules was used at stage 2 to support
reprogramming, only rare conversion of piPSCs to human ESC-like
iPSCs could be observed, suggesting that the transgene expression
during expansion in mTeSR1 was insufficient to reactivate the
expression of the endogenous pluripotent genes in most piPSCs.
Thus we examined whether it was possible to improve episomal
reprogramming by adding additional cytokines in the N2B27
medium supplemented with small molecules (stage 2). Of factors
that are involved in the proliferation of human ESCs, bFGF and
TGF-b/Activin/Nodal signaling are of particular importance. As
inhibitionof TGF-b/Activin/Nodal signalingbyA-83-01facilitated
reprogramming (Fig. 1A), we tested the effect of bFGF on episomal
reprogramming. Indeed, addition of high concentration bFGF to
the N2B27 medium yielded reasonable number of human ESC-like
iPSC colonies (test 3) (Fig. 2A). This result was consistent with
previous observations that high concentration bFGF supported
human ESC growth through multiple pathways besides MEK.
Importantly,removalofMEFfeedercellsbyreplacingwith matrigel
yielded even higher reprogramming efficiency (test 4) (Fig. 2A),
consistent with the previous hypothesis that the MEF feeder cells
contained small molecule-mitigating activities. Time-course exper-
iments showed a requirement for an optimal time window of small
molecule treatment (Fig. 2D). Thus, using small molecules and
defined media (test 4) (Fig. 2A), we have established a feeder free
episomal reprogramming method with significantly improved
efficiency (,220 iPSC colonies from 1610
6 input fibroblasts,
,70-fold increase) (Fig. 2D).
Characterizing iPSCs generated with the feeder-free
small molecule-aided episomal reprogramming method
With the newly developed feeder-free reprogramming condi-
tion, we have successfully derived human ESC-like iPSCs from
Figure 1. Improving episomal reprogramming efficiency with small molecules. (A) Effects of PD0325901 (P, 0.5 mM), CHIR99021(C, 3 mM),
A-83-01(A, 0.5 mM), hLIF (L, 1000 U/ml) and HA-100 (H, 10 mM) on episomal reprogramming. Transfected human foreskin fibroblasts were plated to
MEF feeder cells. MEF-conditioned human ESC medium supplemented with 100 ng/ml bFGF (CM100) was used to support reprogramming. Different
combinations of small molecules and hLIF were added throughout reprogramming starting on day 4 post-transfection. (B) Temporal requirement of
small molecule treatment for improved episomal reprogramming. PCALH was added to CM100 for different days during reprogramming. Alkaline
phosphatase positive iPSC colonies with typical human ESC morphology (e.g. compact colonies, high nucleus-to-cytoplasm ratios and prominent
nucleoli) were counted on day 22–23 post-transfection. The number of iPSC colonies was from ,0.33610
6 input cells. Data shown are mean 6
standard error (SEM) (n=3). (C) Extensive differentiation of the newly derived iPSCs (p3) in the presence of small molecules. When expanded in
human ESC medium or MEF-conditioned human ESC medium supplemented with small molecules on MEF feeder cells, the iPSCs derived with the
continuous presence of small molecules exhibited extensive differentiation. The addition of bFGF in the culture medium had no effect. Black arrow:
undifferentiated iPSC colonies; white arrows: differentiated colonies. Scale bars: 100 mm.
doi:10.1371/journal.pone.0017557.g001
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mTeSR1, these iPSCs showed typical human ESC morphology
(e.g. compact colonies, high nucleus-to-cytoplasm ratios and
prominent nucleoli), and had normal karyotypes (Fig. 3 and Fig.
S3). Most iPSC colonies showed no transgene expression or
genomic integration, and had completely lost episomal vectors
after about 14 passages as demonstrated by PCR and RT-PCR
analysis (Fig. 3C and Fig. S3C). They expressed typical human
ESC-specific antigens (SSEA-3, SSEA-4, Tra-1-60 and Tra-1-81),
down-regulated the expression of the fibroblast marker CD44 (Fig.
S3D), and reactivated the expression of the endogenous plurip-
otent genes (OCT4, NANOG, SOX2 and LIN28) (Fig. 3D). Both the
OCT4 and NANOG promoters were demethylated in these iPSCs,
similar to human ESCs and in contrast to the parental fibroblasts
and piPSCs (Fig. 3E). When injected into immunocompromised
mice, they formed teratomas consisting of derivatives of all three
germ layers, demonstrating the pluripotency of these iPSCs (Fig. 3F
and Fig. S3E).
Episomal reprogramming of different human somatic cell
types
Using human fibroblasts, we have successfully established a
feeder-free small molecule-aided episomal reprogramming meth-
od. Though the reprogramming efficiency was high enough to
enable routine iPSC derivation from human adult fibroblasts, we
sought to further improve the efficiency by modifying the episomal
vectors. Our previous work demonstrated that the balance
between the expression of different transgenes had great impact
on the reprogramming efficiency [19]. Since the transgene
expression from different episomal vectors differs, we tested the
two episomal vector combinations that were previously shown to
Figure 2. Developing a feeder-free condition for episomal reprogramming. (A) Effects of MEF feeder cells, matrigel and culture media on
episomal reprogramming. Transfected human foreskin fibroblasts were plated to MEF feeder cell-seeded or matrigel-coated 10-cm dishes, and
subjected to different reprogramming culture conditions. Alkaline phosphatase positive (AP+) colonies were counted on day 18–21 post-transfection.
The number of AP+ colonies was from ,0.33610
6 input cells. Data shown are mean 6 SEM (n=3). N2B27: DMEM/F12 medium supplemented with
N-2 and B-27; N2B27-100: N2B27 medium supplemented with 100 ng/ml bFGF. (B) Bright-field images of a piPSC colony from test 2 and a typical
human ESC-like iPSC colony from test 1, 3 or 4. Scale bars: 100 mm. (C) Quantitative RT-PCR analysis of OCT4 and NANOG expression in piPSC clone 1
to 4 (c1 to c4, p3). Total: both endogenous and transgene expression. Human H1 ESCs (H1ESC, p32) were used as a control. Data shown are mean 6
SEM (n=3). (D) Temporal requirement of small molecule treatment for feeder-free episomal reprogramming (test 4) (Fig. 2A). Transfected human
foreskin fibroblasts were plated to matrigel-coated 10-cm dishes. PCALH was added to the N2B27-100 medium for different days at stage 2 of
reprogramming. Alkaline phosphatase positive iPSC colonies were counted on day 22 post-transfection. The number of iPSC colonies was from
,0.33610
6 input cells. Data shown are mean 6 SEM (n=3).
doi:10.1371/journal.pone.0017557.g002
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7F-1, which was used for the studies above, and a three-vector
combination 7F-2. Both combinations contain the expression
cassettes for all seven transgenes (OCT4, SOX2, NANOG, LIN28, c-
MYC, KLF4 and SV40LT). As shown in Figure 4A, the three-vector
combination 7F-2 consistently yielded more iPSC colonies than
the two-vector combination 7F-1. More importantly, the replace-
ment of c-MYC in the three-vector combination 7F-2 with
transformation-deficient LMYC further improved the episomal
reprogramming efficiency (,1000 iPSC colonies from 1610
6
input fibroblasts) (Fig. 4A), which is consistent with earlier studies
[30]. Thus with LMYC, the small molecule-aided episomal
reprogramming method is robust for human skin fibroblasts.
Since skin fibroblast might contain higher number of somatic
mutations, they might not be an ideal cell type for the production
of clinical-grade human iPSCs. We tested episomal reprogram-
ming of additional cell types that are readily available from human
donors, specifically, adipose tissue derived cells and cord blood
cells. As shown in Figure 4B and 4C, the small molecule-aided
episomal reprogramming method could be easily adapted to these
two cell types. For adipose tissue-derived cells, the three-vector
combination 7F-2 only yielded very few iPSCs, although many
piPSC colonies were present. Removal of c-MYC and KLF4
(combination 5F: OCT4, SOX2, NANOG, LIN28 and SV40LT),
however, gave rise to numerous iPSC colonies (,1200 iPSC
colonies from 1610
6 input human adult adipose tissue-derived
cells) (Fig. 4B), thus stressing the importance of finding the right
transgene combination for each cell type in order to achieve the
optimal reprogramming efficiency. Cord blood cells, compared to
other somatic cell types, have unique advantages as donor cells for
the production of clinical-grade human iPSCs, since these cells
potentially contain less somatic mutations, and are readily
available. With the small molecule-aided episomal reprogramming
method, high reprogramming efficiency was also achieved with
these cells (,800 iPSC colonies from 1610
6 input post-expansion
cord blood cells, i.e. ,600 iPSC colonies per 1610
4 input freshly
isolated cord blood CD34+ cells with 75-fold expansion during 7-
day culture) (Fig. 4C).
Discussion
In this report, using a combined genetic and chemical
approach, we have successfully established a robust feeder-free
episomal reprogramming method using defined media. Though
developed with fibroblasts, this method was readily adapted to
adipose tissue-derived cells, cord blood cells, and potentially other
cell types easily accessible from human donors. Additional features
can be introduced into episomal vectors to further improve
reprogramming efficiency. For example, the current episomal
vectors have elements necessary for bacterial propagation, which
contain many CpG islands known to contribute to transgene
silencing [31]. It is possible to minimize transgene silencing by
Figure 3. Characterization of iPSCs derived using the small molecule-aided feeder-free condition. (A) Bright-field image of iPSCs derived
from human adult skin fibroblasts (iPS(SK46) clone 2). Scale bar: 100 mm. (B) G-banding chromosome analysis of iPS(SK46) clone 2 (p17). (C) PCR
analysis of reprogramming vectors in iPSCs. E: episomal DNA; G: genomic DNA; NF: neonatal foreskin fibroblasts (p5); iPSF7 clone 1 to 3: iPSCs derived
from neonatal foreskin fibroblasts (p26); AF: adult skin fibroblasts (p6); iPS(SK46) clone 1 to 3: iPSCs derived from adult skin fibroblasts (p22). piPSC
derived from human foreskin fibroblasts (p4) were used as controls. T-OCT4: transgene OCT4; T-SOX2: transgene SOX2; T-NANOG: transgene NANOG; T-
LIN28: transgene LIN28; T-c-MYC: transgene c-MYC; T1-KLF4: transgene KLF4 (1); T2-KLF4: transgene KLF4 (2); T-SV40LT: transgene SV40LT; OCT4:
endogenous OCT4. 32 PCR cycles were used for all primer sets. (D) Quantitative RT-PCR analysis of the endogenous OCT4, NANOG, SOX2 and LIN28
expression in iPSC clones. Data shown are mean 6 SEM (n=3). (E) Bisulfite-sequencing analysis of the methylation status of the OCT4 and NANOG
promoters in iPSC clones. Open circles indicate unmethylated, and filled circles indicate methylated CpG dinucleotides. (F) Hematoxylin and eosin
staining of teratoma sections of iPSC(SK46) clone 2. Teratomas were obtained from all iPSC clones. Left panel: neural tissue (ectoderm); middle panel:
cartilage (mesoderm); right panel: gut epithelium (endoderm). Scale bars: 100 mm.
doi:10.1371/journal.pone.0017557.g003
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recombination to produce minicircle oriP/EBNA-1 episomal
vectors. Nevertheless, the current method is robust enough for
the routine derivation of footprint-free iPSCs from different
somatic cell types and from many human donor samples.
Selection of the right episomal vector combination and
transgene combination appeared to be important for achieving
optimal reprogramming efficiency for different somatic cell types
(Fig. 4A and 4B), likely reflecting their different requirement of
balanced transgene expression. Since only a single transfection is
needed for episomal reprogramming, this method could be readily
applied to many cell types including blood cells such as cord blood
cells, although peripheral blood cells might represent an ideal cell
source for large-scale studies as established procedures are readily
available for blood handling (e.g. collection, cryopreservation,
shipping and cell isolation). It is interesting to see how well this
method can be applied to peripheral blood cells, particularly cells
without genomic rearrangements. The current episomal repro-
gramming method used matrigel as the matrix to support
reprogramming and iPSC expansion due to its affordability. This,
however, introduced undefined components into the method. For
the production of clinical-grade human iPSCs, the matrigel can
most likely be replaced with defined matrix that supports both
donor cell and iPSC growth, such as vitronectin [32]. The
disadvantage with the episomal method, compared to mRNA-
mediated reprogramming [17], is that the iPSCs will need to
undergo multiple passages to completely lose episomal vectors (e.g.
,14 passages for fibroblast-derived iPSCs). This, however, will
unlikely present a problem in applications, since iPSCs will need to
undergo multiple passages to be rid of epigenetic memory of the
donor cells [18], and to be fully characterized for downstream
applications.
Episomal reprogramming in the presence of small molecules
appeared to progress through a distinct intermediate stage -
piPSCs (Fig. 2B), as the same cells were obtained when the N2B27
medium was supplemented with bFGF in test 2 (Fig. 2A). These
piPSCs expressed alkaline phosphatase, could be continuously
passaged in the presence of small molecules, and retained episomal
reprogramming vectors, transgene expression and the ability to
give rise to human ESC-like iPSCs upon withdrawal of small
molecules. The generation of these piPSCs depended on both the
SV40LT expression and the small molecule treatment, since none
of these piPSCs could be observed in the absence of the SV40 LT
expression or the small molecules. In our previous report, we
included SV40LT to counteract the toxic effects caused by c-MYC
overexpression [19]. The role of SV40LT in reprogramming,
however, is rather controversial. It was initially used in
combination with OCT4, SOX2, c-MYC and KLF4 to reprogram
human fibroblasts, but was found to be absent from the iPSCs
generated [33]. This suggested that the SV40LT expression did
not contribute to iPSC derivation. A second report showed that
the SV40LT expression enhanced both the reprogramming
efficiency and the reprogramming pace [34]. Results from our
own work showed that although the SV40LT expression greatly
facilitated the appearance of reprogramming intermediates, its
continuous expression blocked the iPSC generation (unpublished
data). With the small molecule-aided episomal reprogramming in
defined media, the SV40LT expression seemed critical, since no
Figure 4. Optimizing episomal vector and transgene combinations for small molecule-aided reprogramming of different human
somatic cells. (A) Effects of different episomal vector combinations and transformation-deficient LMYC on the reprogramming of human fibroblasts.
Transfected human foreskin fibroblasts (HFFs) were plated to matrigel-coated 10-cm dishes. N2B27-100 medium supplemented with PCALH was used
to support reprogramming between day 2 and 13 post-transfection, followed by mTeSR1 for expansion. The number of iPSC colonies (from
,0.33610
6 input cells) was counted on day 21 post-transfection. Data shown are mean 6 SEM (n=3). (B) Effects of different transgene combinations
on the reprogramming of human adult adipose tissue-derived stem cells (AdSCs). Transfected adipose tissue-derived stem cells were plated to
matrigel-coated 10-cm dishes. N2B27-100 medium supplemented with PCALH was used to support reprogramming between day 2 and 11 post-
transfection, followed by mTeSR1 for expansion. The number of iPSC colonies (from ,0.35610
6 input cells) was counted on day 21 post-transfection.
(C) Effects of transformation-deficient LMYC on the reprogramming of human cord blood (CB) cells. Purified human cord blood CD34+ cells were
expanded in culture for 7 days (,75 fold expansion). Following expansion, the cord blood cells were nucleofected with episomal vectors and plated
to fibronectin/matrigel-coated 6-well plates. N2B27-100 medium supplemented with PCALH was used to support reprogramming between day 2 and
11 post-transfection, followed by mTeSR1 for expansion. The number of iPSC colonies (from ,0.17610
6 post-expansion input cells) was counted on
day 17 post-transfection. Data shown are mean 6 SEM (n=6).
doi:10.1371/journal.pone.0017557.g004
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Truncated mutants of SV40LT such as its transformation domain
(N-terminal 147 amino acids) and p53-binding domain failed to
replace the full-length SV40LT (unpublished data). It remains an
intriguing question how the combination of the SV40LT
expression and small molecule treatments enables the prolonged
retention of oriP/EBNA-1-based reprogramming vectors and
transgene expression. More importantly, due to this distinct
reprogramming intermediate stage, it will be of great interest to
characterize the iPSCs obtained with this method in details, e.g.
the mutation rate arising during reprogramming and the
epigenetic memory retention. This will help address the question
whether the quality of iPSCs is significantly affected by their
derivation methods.
In summary, using defined media, we have successfully
established a robust feeder-free episomal reprogramming method,
which applies to different somatic cell types readily available from
human donors. This method can be used for the derivation of
footprint-free iPSCs from many donor samples, and can be easily
adapted to the production of clinical-grade human iPSCs.
Materials and Methods
Ethics Statement
All human primary cells were generated in vitro from tissue
samples from human donors with appropriate written informed
consent given to the commercial providers.
All mouse work was conducted according to relevant national
and international guidelines under the approval of the Cellular
Dynamics International Animal Care and Use Committee. As a
private company, our animal facility does not provide a permit
number or approval ID since mouse is not a protected species.
Cell culture
Human ESCs and iPSCs were maintained on irradiated MEFs
in DMEM/F12 culture medium supplemented with 20%
KnockOut serum replacement, 0.1 mM non-essential amino
acids, 1 mM GlutaMAX (all from Invitrogen, Carlsbad, CA),
0.1 mM b-mercaptoethanol (Sigma, St. Louis, MO) and 100 ng/
ml zebrafish basic fibroblast growth factor (zbFGF) [19]. MEF-
conditioned human ESC medium was prepared as previously
described [35]. Human newborn foreskin fibroblasts (Cat# CRL-
2097, ATCC, Manassas, MA) and adult skin fibroblasts (Cat#
CRL-2106, ATCC) were cultured in DMEM (Invitrogen)
supplemented with 10% heat-inactivated fetal bovine serum
(FBS, HyClone Laboratories, Loan, UT), 0.1 mM non-essential
amino acids, 1 mM GlutaMAX, 0.1 mM b-mercaptoethanol and
4 ng/ml zbFGF. Human adult adipose tissue-derived stem cells
(Cat# ASC-F, ZenBio, Research Triangle Park, NC) was cultured
in MesenCult-XF basal medium supplemented with 16Mesen-
Cult-XF supplement (STEMCELL Technologies, Vancouver, BC,
Canada) and 2 mM GlutaMAX on collagen (60 mg per 10-cm
dish)/fibronectin (18 mg per 10-cm dish)-coated 10-cm dishes.
Human cord blood CD34+ cells were obtained from STEMCELL
Technologies (Cat# CB008F-S), and expanded on fibronectin-
coated plates in CD34+ cell expansion medium - StemSpan
SFEM (STEMCELL Technologies) supplemented with EX-
CYTE growth enhancement media supplement (1:1000, Milli-
pore, Billerica, MA), 2 mM GlutaMAX, 250 ng/ml SCF, 250 ng/
ml FLT3L, 100 ng/ml TPO, 20 ng/ml IL-3, 50 ng/ml IL-6 and
10 ng/ml sIL6-R (all from Peprotech, Rocky Hill, NJ).
The feeder-free culture of human ESCs and iPSCs on matrigel
(BD Biosciences, Bedford, MA) in mTeSR1 (STEMCELL
Technologies) was carried out as previously described with
modifications in the passaging procedure [36]. Briefly EDTA
splitting method was employed. When human ESCs and iPSCs
reach confluence, cells were washed once with PBS free of Ca
2+
and Mg
2+, and incubated with 0.5 mM EDTA for 8 minutes at
37uC (2 ml/well of 6-well plate). After incubation, the EDTA
solution was removed and fresh mTeSR1 (2 ml/well of 6-well
plate) was added dropwise to each well for cell detachment. Most
cells came off the plate with gentle shaking. Dissociated cells were
then immediately dispersed into freshly prepared matrigel plates
prefilled with mTeSR1. To improve cell attachment and survival,
the ROCK inhibitor HA-100 (10 mM, Santa Cruz Biotechnology,
Santa Cruz, CA) was added to mTeSR1 for 1 day during
passaging. With this method, human ESCs and iPSCs were
passaged every 3 to 4 days at a splitting ratio of 1:8 for optimal
growth.
Improve episomal reprogramming of human fibroblasts
with small molecules
Episomal reprogramming vectors containing expression cas-
settes for human OCT4, SOX2, NANOG, LIN28, c-MYC, KLF4 and
SV40LT transgenes were as previously described [19]. Specifically,
vector pEP4EO2SCK2MEN2L and pEP4EO2SET2K (combina-
tion 7F-1, Fig. S1A) were used for reprogramming optimization.
About 7.3 mg of vector pEP4EO2SCK2MEN2L and 3.2 mgo f
pEP4EO2SET2K were co-transfected into ,1.0610
6 human
neonatal foreskin fibroblasts via nucleofection (VPD-1001 with
program U-20, Amaxa, Walkersville, MD). Transfected fibroblasts
were plated directly to 3610-cm MEF-seeded or matrigel-coated
dishes in fibroblast culture medium. On day one post-transfection,
the fibroblast medium was replaced with MEF-conditioned human
ESC medium supplemented with 100 ng/ml zbFGF (CM100), or
chemically defined N2B27 medium (N2B27), or N2B27 medium
supplemented with 100 ng/ml zbFGF (N2B27-100). The N2B27
medium consists of DMEM/F12 culture medium supplemented
with N-2 supplement (16, Invitrogen), B-27 supplement (16,
Invitrogen), 0.1 mM non-essential amino acids, 1 mM Gluta-
MAX, and 0.1 mM b-mercaptoethanol. Where applied, small
molecules PD0325901 (P, 0.5 mM), CHIR99021(C, 3 mM), A-83-
01(A, 0.5 mM) (all from Stemgent, San Diego, CA), hLIF (L,
1000 U/ml, Millipore) and HA-100 (H, 10 mM) were added to
reprogramming culture. Culture medium was refreshed every two
days. Alkaline phosphatase staining (Cat# SCR004, Millipore)
was performed in subsets of reprogramming experiments to
facilitate the identification of iPSCs. Briefly, cells were fixed in 2%
paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA)
for 30 minutes at room temperature before staining according to
manufacturer’s protocol. Authentic iPSC colonies were stained
positive for alkaline phosphatase, and showed morphology typical
of human ESCs (e.g. compact colonies, high nucleus-to-cytoplasm
ratios and prominent nucleoli) (Fig. S4). Episomal reprogramming
of human adult skin fibroblasts was carried out similarly to that of
foreskin fibroblasts. To characterize the newly derived iPSCs,
iPSC colonies were picked directly onto matrigel-coated 12-well
plates in mTeSR1. EDTA splitting method was employed to
facilitate iPSC expansion and removal of differentiated cells.
Complete loss of episomal vectors was generally achieved around
passage 14 for fibroblast-derived iPSC clones.
Optimizing episomal vector and transgene combinations
for reprogramming human fibroblasts, adult adipose
tissue-derived cells and cord blood cells
Episomal reprogramming vector combinations tested were
shown in Figure S1. For each nucleofection, the following amount
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MEN2L and 3.2 mg of pEP4EO2SET2K); combination 7F-2
(3.0 mg of pEP4EO2SEN2K, 3.2 mg of pEP4EO2SET2K and
2.4 mg of pCEP4-M2L); combination 5F (2.8 mg of pEP4EO2-
SEN2L and 3.2 mg of pEP4EO2SET2N). To test the effect of
transformation-deficient LMYC on episomal reprogramming, the
coding region of LMYC was cloned via PCR from human ESCs
and used to replace the coding region of c-MYC in the vector
pCEP4-M2L of combination 7F-2.
Reprogramming of human foreskin fibroblasts was carried out
as described above. Briefly transfected fibroblasts (,1.0610
6 cells
per nucleofection) were plated directly to 3610-cm matrigel-
coated dishes in fibroblast culture medium. On day 2 post-
transfection, the fibroblast medium was replaced with chemically
defined N2B27-100 supplemented with PCALH. Culture medium
was refreshed every two days. mTeSR1 was used to expand iPSCs
on day 13 post-transfection. The total number of iPSC colonies
was counted on day 21 post-transfection.
Reprogramming of human adult adipose tissue-derived cells was
carried out similarly to that of human fibroblasts. Briefly,
nucleofected adipose tissue-derived cells (VPE-1001 with program
A-33, Amaxa, ,0.7610
6 cells per nucleofection) were plated
directly to 2610-cm matrigel-coated dishes in fresh adipose tissue-
derived cell culture medium. N2B27-100 supplemented with
PCALH was used to support reprogramming between day 2 and
11 post-transfection followed by mTeSR1 for iPSC expansion.
The total number of iPSC colonies was counted on day 21 post-
transfection.
Reprogramming of cord blood cells was similar to that of
fibroblasts and adipose tissue-derived cells. Due to the limited
number of cord blood CD34+ cells and to improve the initial cell
survival following nucleofection, frozen CD34+ cells from
STEMCELL Technologies were thawed and expanded in the
CD34+ cell expansion medium for about 7 days. The CD34+ cells
showed robust growth in culture (,75 fold expansion). Following
expansion, about 1610
6 cells were transfected with episomal
vectors via nucleofection (VPA-1003 with program T-16, Amaxa),
and plated to one fibronectin/matrigel-coated 6-well plate in
CD34+ cell expansion medium. The fibronectin coating was used
together with matrigel to facilitate the cord blood cell recovery
from nucleofection. N2B27-100 supplemented with PCALH was
used to support reprogramming between day 2 and 11 post-
transfection followed by mTeSR1 for iPSC expansion. The total
number of iPSC colonies was counted on day 17 post-transfection.
RT-PCR expression analysis, PCR analysis of episomal
vectors, bisulfite-sequencing analysis, flow cytometry
analysis and karyotyping
PCR, RT-PCR, flow cytometry analysis were performed as
previously described [2,19]. For PCR analysis, episomal DNA was
purified from human cells using QIAprepH Spin Miniprep Kit
(Qiagen, Valencia, CA) with Proteinase K (NEB, Ipswich, MA)
digestion as previously described [37]. Genomic DNA was isolated
with the traditional phenol/chloroform extraction method. All the
PCR reactions were carried out with pfx DNA polymerase
(Invitrogen) with the amplification buffer used at 2X and the
enhancer solution used at 3X, and with the following program:
initial denaturation for 5 minutes at 94uC; 32 cycles of 94uC for
15 seconds, 55uC for 30 seconds, 68uC for 1 minute; and followed
by 68uC for 7 minutes. For each PCR reaction, the episomal DNA
from 1610
4 cells equivalent or about 0.1 mg genomic DNA was
added as template. Episomal DNA and genomic DNA from
nontransfected fibroblasts were used as negative controls, while
those from piPSCs were used as positive controls. For RT-PCR
analysis, total RNA was prepared as described in the RNeasy Mini
Kit (Qiagen) with on-column DNase I digestion. About 1 mg total
RNA from each sample was used for Oligo(dT)20-primed reverse
transcription as described in the product protocol (SuperScript
TM
III First-Strand Synthesis System, Invitrogen). The PCR reactions
for regular RT-PCR analysis of transgene expression were carried
out with the pfx DNA polymerase (Invitrogen) as described above.
The cDNA from nontransfected fibroblasts and human H1 ESCs
were used as negative controls, while that from piPSCs was used as
positive controls. For each sample, 2 ml of diluted cDNA (1:4) was
added as template in PCR reactions. Quantitative PCR reactions
were carried out with Power SYBRHGreen PCR Master Mix
(LightCyclerH 480 II system, Roche, Indianapolis, IN). The cDNA
from human H1ESC was used as a relative standard. For each
sample, 1 ml of diluted cDNA (1:8) was added as template in PCR
reactions. The expression of genes of interest was normalized to
that of GAPDH in all samples. The methylation status of OCT4 and
NANOG promoters were analyzed using bisulfite sequencing with
MethylCode
TM Bisulfite Conversion Kit (Invitrogen) [19]. All
primers were in Table S1 and antibodies were in Table S2.
Standard G-banding chromosome analysis was carried out in the
Cytogenetics Lab at WiCell Research Institute (Madison, WI).
Teratoma formation
To examine the in vivo differentiation potential of human iPSCs
derived with the new episomal method, iPSCs grown on matrigel
in mTeSR1 were transferred to MEF feeder cells for one passage.
Cells were collected with collagenase treatment, and injected into
hind limb muscles of 6-week-old immunocompromised SCID-
beige mice (one 10-cm dish with 50 to 80% confluence per
injection per mouse) (Harlan, Madison, WI). Two injections were
performed for each iPSC clone. After six to eight weeks, teratomas
were obtained from all injections, which were similar in size as
those from human ESCs and iPSCs generated with previous
methods. The teratomas were dissected and fixed in 10% formalin
(Fisher, Pittsburgh, PA). Samples were embedded in paraffin and
processed with hematoxylin and eosin staining in the Experimental
Pathology Department of McArdle Laboratory for Cancer
Research, University of Wisconsin-Madison, WI.
Supporting Information
Figure S1 Episomal reprogramming vector maps. (A)
Combination 7F-1 contains two vectors: pEP4EO2SCK2MEN2L
and pEP4EO2SET2K. This combination expresses all seven
transgenes: OCT4, SOX2, NANOG, LIN28, c-MYC, KLF4 and
SV40LT.( B) Combination 7F-2 contains three vectors: pEP4EO2-
SEN2K, pEP4EO2SET2K and pCEP4-M2L. This combination
also expresses all seven transgenes: OCT4, SOX2, NANOG, LIN28,
c-MYC, KLF4 and SV40LT.( C) Combination 5F contains two
vectors: pEP4EO2SEN2L and pEP4EO2SET2N. This combina-
tion expresses five transgenes: OCT4, SOX2, NANOG, LIN28 and
SV40LT. pEF: the eukaryotic elongation 1a promoter; pCMV: the
cytomegalovirus immediate-early promoter; IRES2: internal
ribosome entry site 2.
(TIF)
Figure S2 Developing a feeder-free condition for epi-
somal reprogramming. (A) Flow cytometry expression analysis
of human ESC-specific cell surface markers (SSEA-3, SSEA-4,
Tra-1-60 and Tra-1-81) and a fibroblast marker CD44 in piPSCs
(p6). Unfilled: isotype control; filled: antigen staining. (B) PCR
analysis of reprogramming vectors in the episomal DNA isolated
from piPSCs (p7). Lane 1: transgene OCT4 (T-OCT4); Lane 2:
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KLF4); Lane 4: transgene KLF4 (2) (T2-KLF4); Lane 5: transgene
SV40LT (T-SV40LT); Lane 6: transgene SOX2 (T-SOX2); Lane 7:
transgene LIN28 (T-LIN28); Lane 8: transgene c-MYC (T-c-MYC);
Lane 9: endogenous OCT4 (OCT4).
(TIF)
Figure S3 Characterization of iPSCs derived using the
small molecule-aided feeder-free condition. (A) Bright-
field image of iPSCs derived from human foreskin fibroblasts
(iPSF7 clone 1). Scale bar: 100 mm. (B) G-banding chromosome
analysis of iPSF7 clone 1 (p18). (C) RT-PCR analysis of transgene
expression in iPSC clones. NF: neonatal foreskin fibroblasts (p5);
iPSF7 clone 1 to 3: iPSCs derived from neonatal foreskin
fibroblasts (p26); AF: adult skin fibroblasts (p6); iPS(SK46) clone
1 to 3: iPSCs derived from adult skin fibroblasts (p22). H1ESC
(p32) and piPSC (p4) derived from human foreskin fibroblasts were
used as controls. T-OCT4: transgene OCT4; T-SOX2: transgene
SOX2; T-NANOG: transgene NANOG; T-LIN28: transgene
LIN28; T-c-MYC: transgene c-MYC; T1-KLF4: transgene KLF4
(1); T2-KLF4: transgene KLF4 (2); T-SV40LT: transgene
SV40LT; OCT4: endogenous OCT4; GAPDH: endogenous
control. 32 PCR cycles were used for all primer sets except for
T-OCT4 (30 cycles). (D) Flow cytometry expression analysis of
human ESC-specific cell surface markers (SSEA-3, SSEA-4, Tra-
1-60 and Tra-1-81) and the fibroblast-enriched marker CD44.
Unfilled: isotype control; filled: antigen staining. (E) Hematoxylin
and eosin staining of teratoma sections of iPSF7 clone 1. Top
panel: neural tissue (ectoderm); middle panel: cartilage (meso-
derm); bottom panel: gut epithelium (endoderm). Scale bars:
100 mm.
(TIF)
Figure S4 Bright-field (BF) images of an intermediate-
stage colony (non-iPSC) and an iPSC colony stained
positive for alkaline phosphatase. These were typical
colonies observed when fibroblasts were episomally repro-
grammed with small molecule-supplemented CM100 on MEF
feeder cells.
(TIF)
Table S1 Primers for PCR, RT-PCR and bisulfite-
sequencing PCR.
(DOC)
Table S2 Antibodies for flow cytometry analysis.
(DOC)
Acknowledgments
We thank J.A.Thomson, N.Seay, T.Burke for assistance in manuscript
preparation.
Author Contributions
Conceived and designed the experiments: JY. Performed the experiments:
JY KFC MAV JJ YJ. Analyzed the data: JY KFC MAV. Wrote the
manuscript: JY.
References
1. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007)
Induction of pluripotent stem cells from adult human fibroblasts by defined
factors. Cell 131: 861–872.
2. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al.
(2007) Induced pluripotent stem cell lines derived from human somatic cells.
Science 318: 1917–1920.
3. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:
663–676.
4. Liu H, Zhu F, Yong J, Zhang P, Hou P, et al. (2008) Generation of induced
pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell 3:
587–590.
5. Esteban MA, Xu J, Yang J, Peng M, Qin D, et al. (2009) Generation of induced
pluripotent stem cell lines from Tibetan miniature pig. J Biol Chem 284:
17634–17640.
6. Loh YH, Agarwal S, Park IH, Urbach A, Huo H, et al. (2009) Generation of
induced pluripotent stem cells from human blood. Blood 113: 5476–5479.
7. Sun N, Panetta NJ, Gupta DM, Wilson KD, Lee A, et al. (2009) Feeder-free
derivation of induced pluripotent stem cells from adult human adipose stem
cells. Proc Natl Acad Sci U S A 106: 15720–15725.
8. Shimada H, Nakada A, Hashimoto Y, Shigeno K, Shionoya Y, et al. (2010)
Generation of canine induced pluripotent stem cells by retroviral transduction
and chemical inhibitors. Mol Reprod Dev 77: 2.
9. Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent
induced pluripotent stem cells. Nature 448: 313–317.
10. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S (2008)
Generation of mouse induced pluripotent stem cells without viral vectors.
Science 322: 949–953.
11. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K (2008) Induced
pluripotent stem cells generated without viral integration. Science 322: 945–949.
12. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M (2009) Efficient induction
of transgene-free human pluripotent stem cells using a vector based on Sendai
virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad
Ser B Phys Biol Sci 85: 348–362.
13. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, et al. (2009) Virus-free
induction of pluripotency and subsequent excision of reprogramming factors.
Nature 458: 771–775.
14. Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, et al. (2009)
piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells.
Nature 458: 766–770.
15. Zhou H, Wu S, Joo JY, Zhu S, Han DW, et al. (2009) Generation of induced
pluripotent stem cells using recombinant proteins. Cell Stem Cell 4: 381–384.
16. Jia F, Wilson KD, Sun N, Gupta DM, Huang M, et al. (2010) A nonviral
minicircle vector for deriving human iPS cells. Nat Methods 7: 197–199.
17. Warren L, Manos PD, Ahfeldt T, Loh YH, Li H, et al. (2010) Highly efficient
reprogramming to pluripotency and directed differentiation of human cells with
synthetic modified mRNA. Cell Stem Cell 7: 618–630.
18. Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, et al. (2010) Cell type of
origin influences the molecular and functional properties of mouse induced
pluripotent stem cells. Nat Biotechnol 28: 848–855.
19. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, et al. (2009) Human induced
pluripotent stem cells free of vector and transgene sequences. Science 324:
797–801.
20. Middleton T, Sugden B (1994) Retention of plasmid DNA in mammalian cells is
enhanced by binding of the Epstein-Barr virus replication protein EBNA1.
J Virol 68: 4067–4071.
21. Yates JL, Guan N (1991) Epstein-Barr virus-derived plasmids replicate only once
per cell cycle and are not amplified after entry into cells. J Virol 65: 483–488.
22. Nanbo A, Sugden A, Sugden B (2007) The coupling of synthesis and partitioning
of EBV’s plasmid replicon is revealed in live cells. EMBO J 26: 4252–4262.
23. Kameda T, Smuga-Otto K, Thomson JA (2006) A severe de novo methylation
of episomal vectors by human ES cells. Biochem Biophys Res Commun 349:
1269–1277.
24. Lin T, Ambasudhan R, Yuan X, Li W, Hilcove S, et al. (2009) A chemical
platform for improved induction of human iPSCs. Nat Methods 6: 805–808.
25. Nichols J, Smith A (2009) Naive and primed pluripotent states. Cell Stem Cell 4:
487–492.
26. Li W, Wei W, Zhu S, Zhu J, Shi Y, et al. (2009) Generation of rat and human
induced pluripotent stem cells by combining genetic reprogramming and
chemical inhibitors. Cell Stem Cell 4: 16–19.
27. Liu Y, Song Z, Zhao Y, Qin H, Cai J, et al. (2006) A novel chemical-defined
medium with bFGF and N2B27 supplements supports undifferentiated growth
in human embryonic stem cells. Biochem Biophys Res Commun 346: 131–139.
28. Hanna J, Cheng AW, Saha K, Kim J, Lengner CJ, et al. (2010) Human
embryonic stem cells with biological and epigenetic characteristics similar to
those of mouse ESCs. Proc Natl Acad Sci U S A 107: 9222–9227.
29. Buecker C, Chen HH, Polo JM, Daheron L, Bu L, et al. (2010) A murine ESC-
like state facilitates transgenesis and homologous recombination in human
pluripotent stem cells. Cell Stem Cell 6: 535–546.
30. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S (2010)
Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl
Acad Sci U S A 107: 14152–14157.
31. Chen ZY, He CY, Meuse L, Kay MA (2004) Silencing of episomal transgene
expression by plasmid bacterial DNA elements in vivo. Gene Ther 11: 856–864.
Small Molecules Improve Episomal Reprogramming
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e1755732. Braam SR, Zeinstra L, Litjens S, Ward-van Oostwaard D, van den Brink S,
et al. (2008) Recombinant vitronectin is a functionally defined substrate that
supports human embryonic stem cell self-renewal via alphavbeta5 integrin. Stem
Cells 26: 2257–2265.
33. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, et al. (2008) Reprogramming
of human somatic cells to pluripotency with defined factors. Nature 451:
141–146.
34. Mali P, Ye Z, Hommond HH, Yu X, Lin J, et al. (2008) Improved efficiency and
pace of generating induced pluripotent stem cells from human adult and fetal
fibroblasts. Stem Cells 26: 1998–2005.
35. Xu C, Inokuma MS, Denham J, Golds K, Kundu P, et al. (2001) Feeder-free
growth of undifferentiated human embryonic stem cells. Nat Biotechnol 19:
971–974.
36. Ludwig TE, Bergendahl V, Levenstein ME, Yu J, Probasco MD, et al. (2006)
Feeder-independent culture of human embryonic stem cells. Nat Methods 3:
637–646.
37. Ziegler K, Bui T, Frisque RJ, Grandinetti A, Nerurkar VR (2004) A rapid in
vitro polyomavirus DNA replication assay. J Virol Methods 122: 123–127.
Small Molecules Improve Episomal Reprogramming
PLoS ONE | www.plosone.org 10 March 2011 | Volume 6 | Issue 3 | e17557